CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.90 +0.06 (+6.75%)
At close: Oct 1, 2026 · 4:00 PM EDT

CytoMed Therapeutics (GDTC) Short term Debt (2021 - 2026)

Updated

CytoMed Therapeutics (GDTC) recorded Short term Debt of $25,753 in Q2 2023.

Analysis

CytoMed Therapeutics (GDTC) Short term Debt (2021 - 2026) Analysis & Trends

At the end of FY2022, CytoMed Therapeutics reported Short term Debt of $3.4 million, up 47.2% from FY2021.

  • Across earlier years, Short term Debt came in at $2.31 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 CytoMed Therapeutics 9.94 Mn -1.15 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 41,845.00
Dec 31, 2025 40,847.00
Jun 30, 2023 25,753.00
Dec 31, 2022 3.40 Mn
Dec 31, 2021 2.31 Mn
API Access

CytoMed Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=GDTC&period=max&api_key=YOUR_API_KEY